Union Korea Pharm Co., Ltd.

A080720

KR7080720006

Pharmaceuticals

End-of-day quote Korea S.E. Other stock markets 23:00:00 16/05/2024 BST			5-day change	1st Jan Change
6,320 ^KRW	+0.96%		+1.61%	+27.68%

04-25	Union Korea Pharm Co., Ltd. announced that it expects to receive KRW 5 billion in funding from Mark420 Co., Ltd, NBH Capital Inc. and other investors	CI
2023	Union Korea Pharm Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	CI

Union Korea Pharm Co., Ltd. has filed an IPO.

March 30, 2018 at 05:00 am

Union Korea Pharm Co., Ltd. has filed an IPO. Security Name: Shares Security Type: Common Stock PriceRange: KRW 12000 to KRW 14200

Latest news about Union Korea Pharm Co., Ltd.

Union Korea Pharm Co., Ltd. announced that it expects to receive KRW 5 billion in funding from Mark420 Co., Ltd, NBH Capital Inc. and other investors	04-24	CI
Union Korea Pharm Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	15/05/23	CI
Union Korea Pharm Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	23/03/23	CI
Union Korea Pharm Co., Ltd. announces an Equity Buyback for 283,333 shares.	21/06/22	CI
Union Korea Pharm Co., Ltd. authorizes a Buyback Plan.	20/06/22	CI
Union Korea Pharm Co., Ltd.'s Equity Buyback announced on October 13, 2021, has expired.	12/01/22	CI
Union Korea Pharm Co., Ltd. announces an Equity Buyback for 200,000 shares.	13/10/21	CI
Union Korea Pharm Co., Ltd. authorizes a Buyback Plan.	12/10/21	CI
Tranche Update on Union Korea Pharm Co., Ltd.'s Equity Buyback Plan announced on May 18, 2021.	11/06/21	CI
Union Korea Pharm Co., Ltd.'s Equity Buyback announced on May 18, 2021, has closed with 200,000 shares, representing 2.53% for KRW 3,104.7 million.	09/06/21	CI
Union Korea Pharm Co., Ltd. announces an Equity Buyback for 200,000 shares.	18/05/21	CI
Union Korea Pharm Co., Ltd. authorizes a Buyback Plan.	17/05/21	CI
Union Korea Pharm Co., Ltd. announced that it has received KRW 30 billion in funding from a group of investors	03/05/21	CI
Union Korea Pharm Co., Ltd. announced that it expects to receive KRW 30 billion in funding from a group of investors	29/04/21	CI
Union Korea Pharm Co., Ltd. has completed an IPO in the amount of KRW 27 billion.	23/07/18	CI
Union Korea Pharm Co., Ltd. has filed an IPO.	30/03/18	CI

Chart Union Korea Pharm Co., Ltd.

Duration

Period

More charts

UNION KOREA PHARM CO.LTD. is a Korea-based company mainly engaged in the manufacturing and distribution of pharmaceuticals. The Company manufactures and sells specialty medicines through formulations such as solid dosage forms, liquid injections, and cefa powder injections. Major products include antibiotics such as kepodon injection and ceftazime injection 1g for the prevention and treatment of infectious diseases; musculoskeletal drugs for treating arthritis contains unihyal injection and galithio injection; circulatory system dugs for the treatment of cerebrovascular diseases, such as cacetile tab and limasta tab; as well as drugs for digestive system such as digestive disorders. In addition, the Company engaged in the contract manufacturing operation (CMO) business for other pharmaceutical companies. The Company distributes its products within domestic market and to overseas markets including Middle East, Southeast Asia and Latin America.

Sector

Pharmaceuticals

Calendar

13/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Specialty & Advanced Pharmaceuticals

	1st Jan change	Capi.
UNION KOREA PHARM CO., LTD.	+27.68%	33.75M
KYOWA KIRIN CO. LTD.	+10.49%	8.96B
SK BIOPHARMACEUTICALS CO., LTD.	-10.76%	5.19B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD.	+51.58%	4.77B
YUHAN CORPORATION	+12.50%	4.26B
BETTA PHARMACEUTICALS CO., LTD.	-20.70%	2.37B
INDIVIOR PLC	+13.33%	2.3B
CHANGCHUN BCHT BIOTECHNOLOGY CO.	-29.65%	2.21B
SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD.	+19.51%	2.17B
VELOXIS PHARMACEUTICALS A/S	-0.50%	1.64B